A commentary by former Institute of Medicine (IOM) committee members says that ethical challenges are central to persistent "critical weaknesses" in the national system for ensuring drug safety. The commentary is published today in the iNew England Journal of Medicine/i. With a caution against "reactive policymaking," committee co-chairs Ruth Faden, Ph.D., M.P.H., and Steven Goodman, M.D., M.H.S., Ph.D., with fellow committee member Michelle Mello, ...Sunday, 26 August 2012
'Critical Weaknesses' in FDA Postmarket Oversight Caused by Ethical Dilemmas
A commentary by former Institute of Medicine (IOM) committee members says that ethical challenges are central to persistent "critical weaknesses" in the national system for ensuring drug safety. The commentary is published today in the iNew England Journal of Medicine/i. With a caution against "reactive policymaking," committee co-chairs Ruth Faden, Ph.D., M.P.H., and Steven Goodman, M.D., M.H.S., Ph.D., with fellow committee member Michelle Mello, ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment